Applied Biosystems and SAIC-Frederick, Inc. to Collaborate on NCI-Funded Genotyping Studies for Cancer Research.FOSTER CITY, Calif. & WASHINGTON -- Collaboration to Validate TaqMan(R) Drug Metabolism Drug Metabolism/Interactions Definition Drug metabolism is the process by which the body breaks down and converts medication into active chemical substances. Precautions Drugs can interact with other drugs, foods, and beverages. Assays Using HapMap, SNP SNP Scottish National Party Noun 1. SNP - (genetics) genetic variation in a DNA sequence that occurs when a single nucleotide in a genome is altered; SNPs are usually considered to be point mutations that have been evolutionarily 500Cancer, and Other Key Sample Sets for Pharmacogenetic Studies Applied Biosystems (NYSE NYSE See: New York Stock Exchange :ABI Abi (ā`bī) [short for Abijah], in the Bible, King Hezekiah's mother. (Application Binary Interface) A specification for a specific hardware platform combined with the operating system. ), an Applera Corporation business, today announced at the 2006 Annual Meeting of the American Association for Cancer Research Wikipedia is not the place for advertisement or self-advertising. The American Association for Cancer Research (AACR) is an organization based in Philadelphia, Pennsylvania, that focuses on all aspects of cancer research including basic, clinical and translational (AACR AACR American Association for Cancer Research AACR Anglo-American Cataloging Rules AACR Australasian Association of Cancer Registries AACR African Armed Conflicts Resolved ) that it has entered into a collaboration with the Core Genotyping Facility, SAIC-Frederick, Inc., a contractor for the National Cancer Institute (NCI See Liberate. ), on a series of biomarker studies for cancer research. The NCI-funded Core Genotyping Facility will use Applied Biosystems' entire TaqMan(R) Drug Metabolism Genotyping Assay collection to examine genetic variations in the HapMap and SNP500Cancer samples in order to validate additional cancer biomarkers. In support of the NCI, the Core Genotyping Facility is using more than 2,400 TaqMan Drug Metabolism Genotyping Assays to generate the genotypes for samples from the International HapMap Project The International HapMap Project is an organization whose goal is to develop a haplotype map of the human genome (the HapMap), which will describe the common patterns of human genetic variation. and from NCI's SNP500Cancer standard sample panel. In addition, select assays with significant correlation from data analysis will be used to genotype individuals who participated in a pharmacogenetic study at the NCI evaluating treatment for Non-Hodgkin lymphoma. "The objective of this study is to better understand the genetic differences associated with individual responses to cancer treatment," said Dennis A. Gilbert, Ph.D., Chief Scientific Officer for Applied Biosystems. "Because our TaqMan Drug Metabolism Genotyping Assays were developed using extensive computational analysis in combination with assay optimization and validation that identified novel and well-known gene variants, we believe they represent the most complete set of drug metabolism assays available to the scientific research community. We are pleased the SAIC-Frederick, under contract to the NCI, has selected them for this important project and are confident the assays will identify genetic variations important to various cancers for future pharmacogenetic studies and treatment guidelines." The Core Genotyping Facility will use samples from the HapMap project (http://www.hapmap.org/index.html), SNP500Cancer (http://snp500cancer.nci.nih.gov), and Human Diversity Panel (http://www.cephb.fr/HGDP-CEPH-Panel/) as controls to evaluate the genes included in the TaqMan Drug Metabolism Genotyping Assays. Applied Biosystems and the Core Genotyping Facility will jointly analyze the resulting genotype data, and compare resulting data with previously published genotype and/or sequencing data for the same variants and individuals. Final data meeting concordance/Mendelian transmission thresholds will be posted on the SNP500Cancer website (http://SNP500Cancer.nci.nih.gov) displaying the observed minor allele frequency, context sequences, and assay ordering information. The collaborators also plan to publish further findings. About the TaqMan Drug Metabolism Genotyping Assays The TaqMan(R) Drug Metabolism Genotyping Assays are a collection of ready-to-use assays that detect polymorphisms within approximately 220 genes identified as phase I, phase II, and transport genes within the drug metabolism pathways. It is believed that some polymorphisms within these genes cause differences for drug efficacy between individuals. Other polymorphisms within these genes are believed to be associated with individuals who have a higher risk for certain diseases. The TaqMan Drug Metabolism Genotyping Assay collection comprises more than 2,400 individual assays for research purposes only. One tube contains two allele allele (əlēl`): see genetics. allele Any one of two or more alternative forms of a gene that may occur alternatively at a given site on a chromosome. specific TaqMan probes and a primer pair to detect individual polymorphisms. All assays have been extensively characterized within this collection with 180 genotypes generated per assay. Where possible, information from the common public allele websites has been mapped to individual assays. For more information, please see http://dme.appliedbiosystems.com About Applera Corporation and Applied Biosystems Applera Corporation consists of two operating groups. The Applied Biosystems Group serves the life science industry and research community by developing and marketing instrument-based systems, consumables, software, and services. Customers use these tools to analyze nucleic acids Nucleic acids The cellular molecules DNA and RNA that act as coded instructions for the production of proteins and are copied for transmission of inherited traits. (DNA DNA: see nucleic acid. DNA or deoxyribonucleic acid One of two types of nucleic acid (the other is RNA); a complex organic compound found in all living cells and many viruses. It is the chemical substance of genes. and RNA RNA: see nucleic acid. RNA in full ribonucleic acid One of the two main types of nucleic acid (the other being DNA), which functions in cellular protein synthesis in all living cells and replaces DNA as the carrier of genetic ), small molecules, and proteins to make scientific discoveries and develop new pharmaceuticals. Applied Biosystems' products also serve the needs of some markets outside of life science research, which we refer to as "applied markets," such as the fields of: human identity testing (forensic and paternity testing paternity testing see parentage testing. ); biosecurity, which refers to products needed in response to the threat of biological terrorism and other malicious, accidental, and natural biological dangers; and quality and safety testing, for example in food and the environment. Applied Biosystems is headquartered in Foster City, CA, and reported sales of nearly $1.8 billion during fiscal 2005. The Celera Genomics Group is focused on discovery, development, and commercialization of diagnostic products as well as leveraging its proteomic, bioinformatic, and genomic capabilities to identify and validate drug targets, and is also seeking to advance therapeutic antibody and selected small molecule drug programs in collaboration with global technology and market leaders. Information about Applera Corporation, including reports and other information filed by the company with the Securities and Exchange Commission, is available at http://www.applera.com, or by telephoning 800.762.6923. Information about Applied Biosystems is available at http://www.appliedbiosystems.com. Applied Biosystems Forward Looking Statements Certain statements in this press release are forward-looking. These may be identified by the use of forward-looking words or phrases such as "should," "expect," and "planned," among others. These forward-looking statements are based on Applera Corporation's current expectations. The Private Securities Litigation Reform Act The Private Securities Litigation Reform Act of 1995 (PSLRA) implemented several significant substantive changes affecting certain cases brought under the federal securities laws, including changes related to pleading, discovery, liability, class representation and awards fees and of 1995 provides a "safe harbor Safe Harbor 1. A legal provision to reduce or eliminate liability as long as good faith is demonstrated. 2. A form of shark repellent implemented by a target company acquiring a business that is so poorly regulated that the target itself is less attractive. " for such forward-looking statements. In order to comply with the terms of the safe harbor, Applera Corporation notes that a variety of factors could cause actual results and experience to differ materially from the anticipated results or other expectations expressed in such forward-looking statements. These factors include but are not limited to: (1) rapidly changing technology and dependence on the development and customer acceptance of new products; (2) sales dependent on customers' capital spending policies and government-sponsored research; and (3) other factors that might be described from time to time in Applera Corporation's filings with the Securities and Exchange Commission. All information in this press release is as of the date of the release, and Applera does not undertake any duty to update this information, including any forward-looking statements, unless required by law. For Research Use Only. Not for use in diagnostic procedures. The purchase of TaqMan(R) DME (Distributed Management Environment) A network monitoring and control protocol defined by the Open Software Foundation (now The Open Group). DME was not widely used. DME - Distributed Management Environment Assays includes an immunity from suit under patents specified in the product inserts to use only the amount purchased for the purchaser's own internal research when used with an Authorized 5' Nuclease nuclease /nu·cle·ase/ (noo´kle-as) any of a group of enzymes that split nucleic acids into nucleotides and other products. nu·cle·ase n. Core Kit. No other patent rights are conveyed expressly, by implication, or by estoppel A legal principle that bars a party from denying or alleging a certain fact owing to that party's previous conduct, allegation, or denial. The rationale behind estoppel is to prevent injustice owing to inconsistency or Fraud. . Further information on purchasing licenses may be obtained from the Director of Licensing, Applied Biosystems, 850 Lincoln Centre Drive, Foster City, California
Copyright(C) 2006. Applied Biosystems. All rights reserved. Applied Biosystems and Celera are registered trademarks and Applera, Celera Diagnostics, Celera Genomics, and Celera Discovery System are trademarks of Applera Corporation or its subsidiaries in the US and/or certain other countries. TaqMan is a registered trademark of Roche Molecular Systems, Inc. |
|
||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion